The following learning assessment is for the maiCE article I-131 Use in Nuclear Medicine: Mechanisms, Safety, and Protocols. First, open the CE article by clicking here. Then, complete the assessment by entering your name and email and selecting "Start" below. This CE activity is worth 1. 0 Category A CE credit (RCEEM AHRA), accepted by the ARRT and the NMTCB. A score of 75% or greater must be scored to obtain credit. Your Certificate of CE Completion will be emailed to the address you use to register this test. Your name will appear on your Certificate of CE Completion as you enter it below. Please include the full name you would like on your certificate as well as any credentials.
Half-life of the isotope
Size of the isotope
Gamma-radiation emitted by the isotope
Beta-particles emitted by the isotope
Method of delivery of the isotope
8 seconds
8 minutes
8 days
8 months
8 years
Alpha
Beta
Gamma
A & b
B & c
Tissue
Secretion
Hormone
Enzyme
10%
20%
30%
40%
50%
1930s
1940s
1950s
1960s
1970s
Thyroiditis
Hyperthyroidism
Hypothyroidism
A & b
B & c
I-131 radiation is detectable outside of the patient body as well as excreted through their body fluid
Diseases that I-131 treat are communicable
I-131 treatment can cause susceptibility to communicable disease
All of the above
Injectable fluid
Pill
Transdermal patch
Radioactive seeds
A & b
Swelling of salivary glands
Nausea
Stomach irritation
Tenderness in the neck area
All of the above
NRC
EPA
FDA
WHO
All of the above
Decrease
Increase
No change
Older
Younger
Obese
A & b
B & c
Hodgkin's lymphoma
Non-Hodgkin's lymphoma
Grave's disease
Multi-nodular goiter
Hyperthyroidism
1 day
2 days
3 days
5 days
No restriction
Clarify the NRC's position on release of I-131 therapy patients
Decrease the occurrence of thyroid cancer
Identify the frequency of I-131 treatment
Clarify the NRC's position on dosage of I-131 therapy patients
Extent of the patient's disease
Destination of the patient after release
Number of therapy sessions the patient has undergone
All of the above
None of the above
Patient; judgement
Licensee; judgement
Licensee; experience
Patient; disease
Patient; family
To strengthen the thyroid tissue
To ablate residual malignant cells
For palliative treatment
To treat metastasis
57%
67%
97%
45%
Wait!
Here's an interesting quiz for you.